Founded in Japan 1890, Santen is one of the oldest ophthalmic pharmaceutical companies and has a long tradition of patient-centred care. Santen offers an extensive track record in developing new products tailored for specific patient needs.
The desire to contribute to the quality of life of people not only in Japan, but also around the world, encouraged Santen Pharmaceutical Co., Ltd. to begin in developing its worldwide presence in the 1990's.
Santen continually strives to grow is practical and scientific knowledge. Vision is our priority and we believe that listening to patients, caregivers and healthcare professionals is essential to improving our services.
During the last decade, Santen has strengthened its presence in Europe to become an important player in the field of ophthalmology.
Santen is one of the few international companies that specialize primarily in ophthalmology. At present, Santen is working with key university research centers and European key opinion leaders to better understand the pathology and disease. Ultimately their work will be used to help facilitate diagnosis and management of this condition.
Santen is committed to protecting and improving vision, especially in ophthalmic disorders requiring new treatment approaches.
Key figures about Santen Europe in existence for 20 years:
Our priority is to develop and acquire new and better solutions that respond to the needs of both patients and healthcare professionals. Santen’s activities primarily focus on ocular surface disorders including dry eye, glaucoma, retina and certain orphan eye diseases.
Research-based, Santen is dedicated to develop innovative therapeutic solutions to treat eye diseases in its four research centers based in Japan, USA, Finland and France.